Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between low temporalis muscle thickness and chemoradiotherapy-induced leukopenia in head and neck squamous cell carcinoma.

Acta oto-laryngologica·2026
Same author

Longitudinal changes in oral and swallowing functions following radiotherapy or chemoradiotherapy in patients with hypopharyngeal cancer: a retrospective study.

BMC oral health·2026
Same author

[Clinical outcomes of idecabtagene vicleucel therapy for relapsed/refractory multiple myeloma: a single-center retrospective analysis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same author

Chronic neutrophilic leukemia with transformation to B-lymphoblastic leukemia.

Leukemia research·2026
Same author

Prognostic Impact of BK Polyomavirus Viremia Detected by Multiplex Plasma PCR Following Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

Clonal Evolution and Lineage Switch from T-Cell Acute Lymphoblastic Leukemia to Acute Myeloid Leukemia in Therapy-Resistant <i>PICALM::MLLT10</i> Leukemia.

EJHaem·2026

Related Experiment Video

Updated: Jun 24, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.

Yuka Harada1, Hironori Harada

  • 1International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Journal of Cellular Physiology
|April 1, 2009
PubMed
Summary

AML1/RUNX1 mutations are key in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Specific mutation types (N-terminal and C-terminal) have distinct effects on cell growth and differentiation, driving MDS pathogenesis.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Point mutations in AML1/RUNX1 are prevalent in myelodysplastic syndrome (MDS) and MDS-related acute myeloid leukemia (MDS/AML).
  • These mutations are considered disease-defining genetic abnormalities, impacting AML1/RUNX1 function.
  • While most mutants lose trans-activation, N-terminal (Ni-type) and C-terminal (Ct-type) mutants exhibit dominant-negative effects, suggesting oncogenic potential.

Purpose of the Study:

  • To investigate the distinct molecular mechanisms and pathogenic roles of Ni-type and Ct-type AML1/RUNX1 mutants in MDS/AML.
  • To elucidate how these different mutant types contribute to the specific clinical features observed in MDS/AML patients.
  • To explore the oncogenic potential and cellular effects of specific AML1/RUNX1 mutants.

Main Methods:

  • Analysis of AML1/RUNX1 point mutations across the entire gene length.
  • Biological analysis using a mouse bone marrow transplantation model with Ni-type (D171N) and Ct-type (S291fsX300) mutants.
  • In vitro studies using human CD34(+) cells to assess molecular mechanisms and cellular behavior.

Main Results:

  • Ni-type and Ct-type AML1/RUNX1 mutants demonstrate distinct molecular mechanisms in human CD34(+) cells.
  • Ni-type mutants induce a differentiation block without promoting cell growth, but BMI-1 co-expression leads to increased blast cells.
  • Ct-type mutants exhibit intrinsic proliferation ability, contributing to MDS pathogenesis by inhibiting hematopoietic stem cell differentiation.

Conclusions:

  • AML1/RUNX1 mutants are central to MDS/AML pathogenesis, acting as initiating factors.
  • Both Ni-type and Ct-type mutants inhibit hematopoietic stem cell differentiation, initiating MDS.
  • Ni-type mutants require additional oncogenic events (like BMI-1 expression) to acquire proliferative capacity, while Ct-type mutants possess inherent proliferation ability.